Terms: = Breast cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Treatment
127 results:
1. Wireless electrostimulation for cancer treatment: An integrated nanoparticle/coaxial fiber mesh platform.
Resina L; Garrudo FFF; Alemán C; Esteves T; Ferreira FC
Biomater Adv; 2024 Jun; 160():213830. PubMed ID: 38552500
[TBL] [Abstract] [Full Text] [Related]
2. Targeted pH- and redox-responsive AuS/micelles with low CMC for highly efficient sonodynamic therapy of metastatic breast cancer.
Maghsoudian S; Motasadizadeh H; Farhadnejad H; Fatahi Y; Fathian Nasab MH; Mahdieh A; Nouri Z; Abdollahi A; Amini M; Atyabi F; Dinarvand R
Biomater Adv; 2024 Apr; 158():213771. PubMed ID: 38271801
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant Auger Electron-Emitting Radioimmunotherapy with [
Facca VJ; Cai Z; Ku A; Georgiou CJ; Reilly RM
Mol Pharm; 2023 Dec; 20(12):6407-6419. PubMed ID: 37983089
[TBL] [Abstract] [Full Text] [Related]
4. Improved antitumor activity through a tyramidyl maslinic acid derivative. Design and validation as drug-loaded electrospun polymeric nanofibers.
Luque C; de la Cabeza Fernández M; Fuentes-Rios D; Cepero A; Contreras-Cáceres R; Doña M; Perazzoli G; Lozano-Chamizo L; Filice M; Marciello M; Gonzalez-Rumayor V; López-Romero JM; Cabeza L; Melguizo C; Prados J
Eur J Pharm Biopharm; 2023 Dec; 193():241-253. PubMed ID: 37972906
[TBL] [Abstract] [Full Text] [Related]
5. A facile, flexible, and multifunctional thermo-chemotherapy system for customized treatment of drug-resistant breast cancer.
Chen L; Nabil A; Fujisawa N; Oe E; Li K; Ebara M
J Control Release; 2023 Nov; 363():550-561. PubMed ID: 37804880
[TBL] [Abstract] [Full Text] [Related]
6. Targeted drug-loaded PLGA-pcl microspheres for specific and localized treatment of triple negative breast cancer.
Nwazojie CC; Obayemi JD; Salifu AA; Borbor-Sawyer SM; Uzonwanne VO; Onyekanne CE; Akpan UM; Onwudiwe KC; Oparah JC; Odusanya OS; Soboyejo WO
J Mater Sci Mater Med; 2023 Aug; 34(8):41. PubMed ID: 37530973
[TBL] [Abstract] [Full Text] [Related]
7. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Kobayashi K; Masuda N; Mizuno T; Miura K; Tokuda Y; Yoshinami T; Kawaguchi H; Ohtani S; Saeki T; Toi M; Takeuchi M; Ito Y
Breast Cancer Res Treat; 2023 Oct; 201(3):409-415. PubMed ID: 37480384
[TBL] [Abstract] [Full Text] [Related]
8. Enzyme/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis.
Xiao P; Tao X; Wang H; Liu H; Feng Y; Zhu Y; Jiang Z; Yin T; Zhang Y; He H; Gou J; Tang X
Expert Opin Drug Deliv; 2023; 20(7):1015-1031. PubMed ID: 37452715
[TBL] [Abstract] [Full Text] [Related]
9. High vegfr3 Expression Reduces Doxorubicin Efficacy in Triple-Negative breast cancer.
Torres-Ruiz S; Tormo E; Garrido-Cano I; Lameirinhas A; Rojo F; Madoz-Gúrpide J; Burgués O; Hernando C; Bermejo B; Martínez MT; Lluch A; Cejalvo JM; Eroles P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835014
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
11. Paclitaxel-loaded liposome-incorporated chitosan (core)/poly(ε-caprolactone)/chitosan (shell) nanofibers for the treatment of breast cancer.
Hasanbegloo K; Banihashem S; Faraji Dizaji B; Bybordi S; Farrokh-Eslamlou N; Abadi PG; Jazi FS; Irani M
Int J Biol Macromol; 2023 Mar; 230():123380. PubMed ID: 36706885
[TBL] [Abstract] [Full Text] [Related]
12. Structure-Activity Relationship Studies Based on 3D-QSAR CoMFA/CoMSIA for Thieno-Pyrimidine Derivatives as Triple Negative breast cancer Inhibitors.
Kim JH; Jeong JH
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432075
[TBL] [Abstract] [Full Text] [Related]
13. 3D printed biodegradable multifunctional implants for effective breast cancer treatment.
Di Luca M; Hoskins C; Corduas F; Onchuru R; Oluwasanmi A; Mariotti D; Conti B; Lamprou DA
Int J Pharm; 2022 Dec; 629():122363. PubMed ID: 36336202
[TBL] [Abstract] [Full Text] [Related]
14. The value of potential immunohistochemical biomarkers and clinicopathological findings in predicting response to neoadjuvant chemotherapy in breast cancer.
Akay E; Eren SK; Özhan N; Arslan A; Karaman H
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7070-7083. PubMed ID: 36263555
[TBL] [Abstract] [Full Text] [Related]
15. Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor treatment for breast cancer.
Kajiwara Y; Iwamoto T; Zhu Y; Kochi M; Shien T; Taira N; Doihara H; Toyooka S
Acta Med Okayama; 2022 Aug; 76(4):399-408. PubMed ID: 36123154
[TBL] [Abstract] [Full Text] [Related]
16. Development of stimulus-sensitive electrospun membranes based on novel biodegradable segmented polyurethane as triggered delivery system for doxorubicin.
Federico S; Martorana A; Pitarresi G; Palumbo FS; Fiorica C; Giammona G
Biomater Adv; 2022 May; 136():212769. PubMed ID: 35929309
[TBL] [Abstract] [Full Text] [Related]
17. Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision.
van de Voort EM; Struik GM; van Streun SP; Verhoef C; Uyl-de Groot CA; Klem TM
Br J Radiol; 2022 Aug; 95(1136):20220117. PubMed ID: 35604725
[TBL] [Abstract] [Full Text] [Related]
18. Lithocholic acid conjugated mPEG-b-pcl micelles for pH responsive delivery to breast cancer cells.
Isik G; Kiziltay A; Hasirci N; Tezcaner A
Int J Pharm; 2022 Jun; 621():121779. PubMed ID: 35500691
[TBL] [Abstract] [Full Text] [Related]
19. Preparing Future Medicine Physicians to Care for cancer Survivors: Project ECHO® in a Novel Internal Medicine and Family Medicine Residency Curriculum.
Choi Y; Chodoff AC; Brown K; Murillo LA; Nesfeder J; Bugayong MT; Peairs KS
J Cancer Educ; 2023 Apr; 38(2):608-617. PubMed ID: 35366218
[TBL] [Abstract] [Full Text] [Related]
20. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
[TBL] [Abstract] [Full Text] [Related]
[Next]
